Articles published by Vedanta Biosciences

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data

August 06, 2026

Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress

April 09, 2026

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis

April 02, 2026

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

August 13, 2025

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 23, 2025

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes

October 16, 2024

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

July 23, 2024

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

May 21, 2024

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Present at Upcoming Investor Conferences

April 29, 2024

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference

March 06, 2024

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

November 28, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium

October 25, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023

October 11, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Participate at Upcoming Investor Conferences

October 05, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation

October 04, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

May 09, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 08, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

April 25, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

April 17, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Present at Upcoming Investor Conferences

January 26, 2023

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress

November 09, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Present at Upcoming Investor Conferences

July 07, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia

June 28, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

June 08, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

May 24, 2022

From Vedanta Biosciences

Via Business Wire

Tickers PRTC

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

April 13, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit

February 23, 2022

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

October 14, 2021

From Vedanta Biosciences

Via Business Wire

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

June 29, 2021

From Vedanta Biosciences

Via Business Wire

Tickers PRTC

Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event

April 29, 2021

From Vedanta Biosciences

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.